The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Drug pathway-associated gene polymorphisms in patients with advanced non-small cell lung cancer receiving first-line platinum-gemcitabine combination chemotherapy: A prospective multicenter observational study.
M. Joerger
No relevant relationships to disclose
S. A. Burgers
No relevant relationships to disclose
P. Baas
No relevant relationships to disclose
E. F. Smit
No relevant relationships to disclose
T. J. Haitjema
No relevant relationships to disclose
M. P. L. Bard
No relevant relationships to disclose
V. D. Doodeman
No relevant relationships to disclose
P. H. M. Smits
No relevant relationships to disclose
A. Vincent
No relevant relationships to disclose
A. Huitema
No relevant relationships to disclose
J. H. Beijnen
No relevant relationships to disclose
J. H. M. Schellens
No relevant relationships to disclose